Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells… Read more
Lyell Immunopharma Inc (LYEL) - Total Assets
Latest total assets as of September 2025: $407.96 Million USD
Based on the latest financial reports, Lyell Immunopharma Inc (LYEL) holds total assets worth $407.96 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lyell Immunopharma Inc - Total Assets Trend (2019–2024)
This chart illustrates how Lyell Immunopharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lyell Immunopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lyell Immunopharma Inc's total assets of $407.96 Million consist of 77.3% current assets and 22.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Lyell Immunopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lyell Immunopharma Inc's current assets represent 77.3% of total assets in 2024, a decrease from 79.2% in 2019.
- Cash Position: Cash and equivalents constituted 21.5% of total assets in 2024, up from 17.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lyell Immunopharma Inc Competitors by Total Assets
Key competitors of Lyell Immunopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lyell Immunopharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lyell Immunopharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lyell Immunopharma Inc is currently not profitable relative to its asset base.
Lyell Immunopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.30 | 13.43 | 12.53 |
| Quick Ratio | 10.30 | 13.43 | 12.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $296.32 Million | $ 416.53 Million | $ 568.26 Million |
Lyell Immunopharma Inc - Advanced Valuation Insights
This section examines the relationship between Lyell Immunopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.64 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -34.6% |
| Total Assets | $490.86 Million |
| Market Capitalization | $243.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lyell Immunopharma Inc's assets below their book value (0.50 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lyell Immunopharma Inc's assets decreased by 34.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lyell Immunopharma Inc (2019–2024)
The table below shows the annual total assets of Lyell Immunopharma Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $490.86 Million | -34.55% |
| 2023-12-31 | $750.03 Million | -20.00% |
| 2022-12-31 | $937.56 Million | -16.84% |
| 2021-12-31 | $1.13 Billion | +24.13% |
| 2020-12-31 | $908.28 Million | +63.47% |
| 2019-12-31 | $555.63 Million | -- |